首页> Pharmaceuticals (Basel, Switzerland)> The Impact of Comorbidities on the Discontinuation of Antifibrotic Therapy in Patients with Idiopathic Pulmonary Fibrosis.

The Impact of Comorbidities on the Discontinuation of Antifibrotic Therapy in Patients with Idiopathic Pulmonary Fibrosis.

导出 OA

翻译打印收藏纠错

第一作者： Stefano,Kette

第一单位： Pulmonology Unit, Department of Medical Surgical and Health Sciences, University of Trieste, Hospital of Cattinara, 34149 Trieste, Italy.

作者： Stefano,Kette ^[1] ; Nicolò,Reccardini ^[1] ; Francesco,Salton ^[1] ; Paola,Confalonieri ^[1] ; Alessia,Andrisano ^[2] ; Maria,Chianese ^[1] ; Anna,De Nes ^[1] ; Marta,Maggisano ^[1] ; Alessandra,Galantino ^[1] ; Salvatore,Nicolosi ^[1] ; Marco,Mari ^[1] ; Andrea,Salotti ^[1] ; Darina,Angoni ^[1] ; Maria,Chernovsky ^[1] ; Michael,Hughes ^[3] ; Marco,Confalonieri ^[1] ; Lucrezia,Mondini ^[1] ; Barbara,Ruaro ^[1]

作者单位： Pulmonology Unit, Department of Medical Surgical and Health Sciences, University of Trieste, Hospital of Cattinara, 34149 Trieste, Italy. ^[1] Pulmonology Unit, Department of Cardio-Thoracic Surgery, Health Integrated Agency of Friuli Venezia Giulia, 33100 Udine, Italy. ^[2] Division of Musculoskeletal and Dermatological Sciences, Faculty of Biology, Medicine and Health, The University of Manchester & Salford Royal NHS Foundation Trust, Manchester M6 8HD, UK. ^[3]

关键词 antifibrotic therapy (AFT)comorbidities idiopathic pulmonary fibrosis (IPF)nintedanib pirfenidone treatable traits

DOI 10.3390/ph18030411

PMID 40143187

发布时间 2025-03-29

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交